| 06/23/2026 5:25 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/23/2026 5:26 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/23/2026 5:19 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/23/2026 3:05 PM | Dyne Therapeutics (1818794) Issuer Greene Barry E (1291963) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 06/23/2026 3:07 PM | Dyne Therapeutics (1818794) Issuer Greene Barry E (1291963) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 3:15 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/22/2026 3:15 PM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/17/2026 3:03 PM | Dyne Therapeutics (1818794) Subject ForDyne B.V. (2019392) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 06/17/2026 3:07 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/17/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/09/2026 4:09 PM | Dyne Therapeutics (1818794) Issuer Stehman-Breen Catherine (1702233) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for DYN and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Dyne Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
|
| 06/09/2026 4:12 PM | Dyne Therapeutics (1818794) Issuer Incerti Carlo (1915358) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:12 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:13 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:13 PM | Dyne Therapeutics (1818794) Issuer Lubner David Charles (1572000) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:15 PM | Dyne Therapeutics (1818794) Issuer HURWITZ EDWARD (1211840) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:06 PM | Dyne Therapeutics (1818794) Issuer Posner Brian S (1372455) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/08/2026 3:05 PM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/03/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/15/2026 11:36 AM | Dyne Therapeutics (1818794) Subject JANUS HENDERSON GROUP PLC (1274173) Filed by | Form SCHEDULE 13G/A | |
| 05/14/2026 3:04 PM | Dyne Therapeutics (1818794) Issuer Kerr Douglas (1814189) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/14/2026 3:05 PM | Dyne Therapeutics (1818794) Issuer Friedl-Naderer Johanna (1915598) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/13/2026 3:55 PM | Dyne Therapeutics (1818794) Subject Lucera Erick (1697616) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/13/2026 3:57 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/11/2026 6:25 AM | Dyne Therapeutics (1818794) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 05/11/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/06/2026 4:09 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 05/06/2026 3:42 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 3:42 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 3:43 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/06/2026 10:13 AM | Dyne Therapeutics (1818794) Subject FMR LLC (315066) Filed by | Form SCHEDULE 13G | |
| 05/05/2026 3:36 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/05/2026 3:36 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/05/2026 3:37 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 3:59 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 3:59 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 3:59 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 05/04/2026 4:00 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/30/2026 4:22 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/28/2026 3:56 PM | Dyne Therapeutics (1818794) Issuer Lubner David Charles (1572000) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/28/2026 3:42 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
Every time Musk needs a company, he buys it (Ad) Musk needed batteries - he built the Gigafactory. Needed solar - acquired SolarCity. Needed data - bought Twitter. The pattern is consistent: when a supplier becomes mission-critical, he acquires it.
Now, with $75 billion raised in the largest IPO in history, one small power infrastructure company is the critical piece his $2 trillion empire can't run without. Dylan Jovine has the name and ticker. See the stock Musk's acquisition playbook says he needs now |
| 04/28/2026 3:43 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/28/2026 3:43 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/28/2026 3:44 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 5:15 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/27/2026 3:48 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 3:48 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 3:48 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/27/2026 3:49 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/24/2026 3:45 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/24/2026 3:46 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/24/2026 3:46 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/24/2026 3:47 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/23/2026 3:45 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/23/2026 3:45 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/23/2026 3:45 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/23/2026 3:46 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/23/2026 3:15 PM | Dyne Therapeutics (1818794) Filer | Form ARS | |
| 04/23/2026 3:15 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/23/2026 3:05 PM | Dyne Therapeutics (1818794) Filer | Form DEF 14A | |
| 04/22/2026 5:27 PM | Dyne Therapeutics (1818794) Issuer Rhodes Jason P (1577014) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/22/2026 3:52 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/22/2026 3:53 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/22/2026 3:53 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/22/2026 3:54 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/21/2026 3:53 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/21/2026 3:53 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/21/2026 3:53 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/21/2026 3:54 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/21/2026 3:15 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/20/2026 3:43 PM | Atlas Venture Associates XI, L.P. (1780068) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/20/2026 3:44 PM | Atlas Venture Opportunity Fund II, L.P. (1885327) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/20/2026 3:44 PM | Atlas Venture Opportunity Fund I, L.P. (1759241) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/20/2026 3:44 PM | Atlas Venture Fund XI, L.P. (1708269) Reporting Dyne Therapeutics (1818794) Subject | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 04/17/2026 3:05 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/09/2026 3:29 PM | Dyne Therapeutics (1818794) Filer | Form PRE 14A | |
| 04/03/2026 3:10 PM | Dyne Therapeutics (1818794) Issuer Lucera Erick (1697616) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 04/01/2026 3:06 PM | Dyne Therapeutics (1818794) Subject Lucera Erick (1697616) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/27/2026 3:14 PM | Dyne Therapeutics (1818794) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 03/26/2026 5:04 PM | Dyne Therapeutics (1818794) Subject VANGUARD GROUP INC (102909) Filed by | Form SCHEDULE 13G/A | |
| 03/13/2026 3:46 PM | Dyne Therapeutics (1818794) Issuer Posner Brian S (1372455) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/13/2026 3:35 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/11/2026 4:27 PM | Dyne Therapeutics (1818794) Issuer Kersten Dirk (1823682) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/10/2026 4:33 PM | Dyne Therapeutics (1818794) Issuer Posner Brian S (1372455) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/09/2026 3:09 PM | Dyne Therapeutics (1818794) Subject ForDyne B.V. (2019392) Reporting | Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
| 03/06/2026 3:08 PM | Cox John (1498428) Reporting Dyne Therapeutics (1818794) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/06/2026 3:09 PM | Dyne Therapeutics (1818794) Issuer Kerr Douglas (1814189) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/06/2026 3:10 PM | Dyne Therapeutics (1818794) Issuer Friedl-Naderer Johanna (1915598) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 03/06/2026 11:57 AM | Dyne Therapeutics (1818794) Subject T. Rowe Price Investment Management, Inc. (1897612) Filed by | Form SCHEDULE 13G/A | |
| 03/02/2026 6:52 AM | Dyne Therapeutics (1818794) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 03/02/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
Elon Musk, Larry Fink & Brian Armstrong are ALL Piling into This (Ad) Elon Musk, BlackRock CEO Larry Fink, and Coinbase CEO Brian Armstrong are all quietly investing in the same technology - and it has nothing to do with AI, crypto, or robotics.
Robinhood founder Vlad Tenev calls it a 'freight train' set to 'eat' the financial system. Yahoo Finance says it 'May Unlock $400 Trillion.' Investing analyst Jeff Brown, who identified Bitcoin, Tesla, and Nvidia early, believes it will be 90 times bigger than AI and 1,900 times bigger than Bitcoin. See Jeff Brown's full breakdown and how to claim your stake today |
| 03/02/2026 6:20 AM | Dyne Therapeutics (1818794) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 01/12/2026 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 01/08/2026 11:15 AM | Dyne Therapeutics (1818794) Subject T. Rowe Price Investment Management, Inc. (1897612) Filed by | Form SCHEDULE 13G | |
| 12/23/2025 3:05 PM | Dyne Therapeutics (1818794) Issuer Karnani Vikram (1699488) Reporting | Form 3 Initial statement of beneficial ownership of securities | |
| 12/23/2025 6:35 AM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/10/2025 3:22 PM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/10/2025 3:31 PM | Dyne Therapeutics (1818794) Filer | Form 424B5 | |
| 12/08/2025 3:19 PM | Dyne Therapeutics (1818794) Filer | Form 424B5 | |
| 12/08/2025 3:07 PM | Dyne Therapeutics (1818794) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |